Pharmafile Logo

News and Press Releases

Heidelberg Pharma’s Lead ADC Candidate HDP-101 Granted Fast Track Designation by US FDA for the Treatment of Multiple Myeloma

Recognizes the potential of HDP-101 to address a serious or life-threatening condition with high unmet medical needs Enables more frequent engagement with FDA and eligibility for rolling review to support...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 23, 2025

Heidelberg Pharma
info@hdpharma.com
Gregor-Mendel-Straße 22 68526 Ladenburg Deutschland

Iksuda to present IKS014 Phase 1 data at ESMO

14 October 2025 -- Newcastle, UK -- Iksuda Therapeutics (Iksuda), the developer of class-leading antibody drug conjugates (ADCs), will present new data from its Phase 1 study of IKS014, a...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 14, 2025

Iksuda
The Biosphere, Draymans Way, Newcastle Helix Newcastle upon Tyne NE4 5BX

Ryvu Therapeutics Announces Strategic Agreement to Support Clinical Trials for BioNTech’s Investigational Cancer Immunotherapies in Poland

Ryvu to support BioNTech in the acceleration of site activation and enrollment of patients for multiple of BioNTech’s priority oncology clinical programs in Poland Ryvu will leverage its clinical network to...

Category: BioManufacturing, Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: September 2, 2025

Ryvu Therapeutics
ryvu@ryvu.com
R&D Center for Innovative Drugs Leona Henryka Sternbacha 2 30-394 Kraków, Poland

HeartBeat.bio and biotx.ai Sign License and Technology Access Agreement to Identify Novel Targets in Heart Failure

7 July 2025 -- Vienna, Austria and Berlin, Germany -- HeartBeat.bio AG and biotx.ai GmbH today announced a strategic partnership to identify and validate novel therapeutic targets in heart failure. The collaboration combines biotx.ai’s causal...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: July 7, 2025

Heartbeat.Bio
office@heartbeat.bio
Vienna Biocenter 6 Dr. Bohr-Gasse 7 A-1030 Vienna Austria

Iksuda Therapeutics receives FDA IND clearance for IKS014

FDA decision will enable Iksuda to expand its ongoing clinical trial in the US, Australia and Singapore Preliminary data from an ongoing dose-escalation study of IKS014 has shown meaningful clinical activity across...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: July 1, 2025

Iksuda
The Biosphere, Draymans Way, Newcastle Helix Newcastle upon Tyne NE4 5BX

Heidelberg Pharma to Present Promising New Clinical Data on its Lead ATAC Candidate HDP-101 at EHA 2025

• HDP-101 demonstrated complete response in one female patient from cohort 5• R&D Webinar to be hosted on 17 June 2025. 15 May 2025 -- Ladenburg, Germany -- Heidelberg Pharma...

Category: BioManufacturing, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 15, 2025

Heidelberg Pharma
info@hdpharma.com
Gregor-Mendel-Straße 22 68526 Ladenburg Deutschland

Medable Releases New Digital Oncology Trial Offering to Reduce Complexity for Sites, Sponsors, Patients, and Caregivers

Integrated solution with self-service capabilities simplifies trial experience for all 13 May 2025 -- California, US -- Medable Inc., a leading provider of clinical development and eCOA technology, today announced...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 13, 2025

Medable
media@medable.com
525 University Ave Suite A70 Palo Alto, CA 94301

iOnctura commences randomized Phase I/II study in non-small cell lung cancer

First patient dosed in study investigating roginolisib + dostarlimab +/- docetaxel in patients with NSCLC who have progressed on prior immunotherapy/chemo Study will evaluate safety of the combination and explore...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 8, 2025

iOnctura
enquiries@ionctura.com
Campus Biotech Innovation Park Avenue Sécheron 15
 1202 Genève
 Switzerland

Redx presents Phase 1 data supporting RXC008 as a novel and well tolerated drug candidate in development for the potential treatment of fibrostenotic Crohn’s disease

Orally administered pan-ROCK inhibitor demonstrated intestinal tissue exposure and target engagement with minimal plasma concentrations A Phase 2 study is being planned. 6 May 2025 -- Alderley Park, UK --...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 6, 2025

Redx Pharma
info@redxpharma.com
Block 33 Mereside, Alderley Park Alderley Edge Macclesfield SK10 4TG UK

Domain Therapeutics Presents Novel Data Addressing Key Challenges in Oncology at AACR 2025

Phase I clinical results of DT-9081, an EP4 receptor antagonist, allowed selection of recommended Phase II dose (RP2D) for further development in solid tumors Preclinical data of DT-7012 position this...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 30, 2025

Domain Therapeutics
contact@domaintherapeutics.com
PARC D'INNOVATION 220 Boulevard Gonthier D'Andernach 67400 Strasbourg - Illkirch - France

Iksuda to present growing ADC pipeline at AACR

Introduces the ProAlk payload series to address the growing challenge of ADC sequencing IKS04 to enter clinical development for gastrointestinal cancers by end of 2025 PermaLink offers stable and scalable...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 25, 2025

Iksuda
The Biosphere, Draymans Way, Newcastle Helix Newcastle upon Tyne NE4 5BX

Mosaic Therapeutics in-licenses two clinical-stage oncology programs from Astex Pharmaceuticals for development as proprietary combination therapies

In-licensing transforms Mosaic from a research and platform company to a clinical-stage oncology business Mosaic will develop proprietary, targeted combination products, supported by proprietary biomarkers, to realise the full potential...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: April 24, 2025

Mosaic Therapeutics
info@mosaic-tx.com
Mosaic Therapeutics Wellcome Genome Campus Cambridge CB10 1DR

Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types

Aggregate analysis of eight clinical trials of patients with advanced non-small cell lung cancer (aNSCLC) was supported by Biodesix, using Bio-Rad Droplet Digital™ PCR technology 23 April 2025 -- Colorado,...

Category: BioManufacturing, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 23, 2025

Biodesix
919 W Dillon Rd, Louisville, CO 80027

Pharming receives positive recommendation from NICE for Joenja▼(leniolisib) as a treatment for APDS

Joenja® is the first and only medicine specifically for APDS to be reimbursed within the NHS Recommended for adult and pediatric patients 12 years of age and older with activated...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 23, 2025

Pharming Group NV
info@pharming.com
Pharming Group N.V. Vondellaan 47 2332 AA Leiden The Netherlands

Boehringer Ingelheim and Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancers

23 April 2025 -- Ingelheim, Germany and Amsterdam, the Netherlands -- Boehringer Ingelheim and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, have...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: April 23, 2025

Boehringer Ingelheim
Binger Strasse 173 55216 Ingelheim am Rhein